Elutia to Present at the LD Micro Main Event XVII Conference on Wednesday, October 30
Elutia (Nasdaq: ELUT), a pioneer in drug-eluting biomatrix products, has announced its participation in the LD Micro Main Event XVII Conference in Los Angeles.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Elutia (Nasdaq: ELUT), a pioneer in drug-eluting biomatrix products, has announced its participation in the LD Micro Main Event XVII Conference in Los Angeles. Dr. Randy Mills, President and CEO, will deliver a presentation on Wednesday, October 30, 2024, at 2:00 p.m. PT (5:00 p.m. ET). The company's management team will also be available for one-on-one meetings with institutional investors, who can schedule appointments through LD Micro representatives or by contacting IR@elutia.com.
Details
News Market Reaction – ELUT
The recorded move for ELUT in the trading session of this news was +2.87%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SILVER SPRING, Md., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a leader in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the LD Micro Main Event XVII Conference in Los Angeles on Wednesday, October 30, 2024, at 2:00 p.m. PT (5:00 p.m. ET).
LD Micro Main Event XVII Conference
Presentation Date: Wednesday, October 30, 2024
Presentation Time: 2:00 p.m. PT (5:00 p.m. ET)
Webcast: Click here
Elutia management will also participate in 1x1 investor meetings. Institutional investors interested in scheduling a meeting may contact an LD Micro representative or email IR@elutia.com.
About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.
Investors:
Matt Steinberg
FINN Partners
matt.steinberg@finnpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.